Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

OBJECTIVE: Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA). Data from these trials were used to identify baseline char...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S., Kang, Young Mo, Yoo, Wan-Hee, Emery, Paul, Weinblatt, Michael E., Keystone, Edward C., Genovese, Mark C., Myung, Gihyun, Baek, Inyoung, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427775/
https://www.ncbi.nlm.nih.gov/pubmed/32795341
http://dx.doi.org/10.1186/s13075-020-02267-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427775/
https://www.ncbi.nlm.nih.gov/pubmed/32795341
http://dx.doi.org/10.1186/s13075-020-02267-z

Ejemplares similares